Overview: NGS Albinism Sequencing TestIntroduction: The NGS Albinism Sequencing Test sequences genes to diagnose albinism, causing vision issues or skin sensitivity. Following 2023 ACMG guidelines, it uses PCR for high specificity, supporting genetic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected albinism, such as oculocutaneous albinism.
Other Names: Albinism Assay, OCA Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Albinism sequencing began in the 1990s with pigmentation research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose albinism, guides treatment, and evaluates patients with vision issues or skin sensitivity.
Test Parameters: 1. Albinism Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of vision issues, skin sensitivity, or albinism symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document vision issues, skin sensitivity, photophobia, or family history of albinism. Include current medications, especially eye-related treatments.
Consent: Written consent required, detailing the tests purpose, albinism implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze albinism genes (e.g., TYR, OCA2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for albinism diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm albinism, guiding vision care or genetic counseling. Negative results may require further genetic testing.
Specialist Consultation: Consult a geneticist or ophthalmologist for result interpretation and treatment planning.
Additional Supporting Tests: Eye exam, skin biopsy, or visual evoked potentials to confirm albinism diagnosis.
Test Limitations: Not all albinism cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: ACMG Albinism Guidelines, 2023; American Journal of Human Genetics, King RA, 2022.
